SCHEMBL2961790

SCHEMBL2961790

Cc1ccc2c(Nc3cc(Cl)ccc3Oc3cccc(C(C)O)c3)ccnc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.42
NR4A2 P43354 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 2/20 0.36
THRB P10828 1/20 0.36
KDR P35968 3/20 0.34
CYP3A4 P08684 2/20 0.34
MAPK1 P28482 2/20 0.34
HSD17B10 Q99714 2/20 0.34
PTGS1 P23219 2/20 0.34
PTGS2 P35354 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MLNR O43193 1/20 0.34
ABCB11 O95342 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CHRM2 P08172 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34
GABRA1 P14867 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2967382 0.88 NR4A2 (0.38) IGF1RNR4A2MEN1KMT2APOLB
SCHEMBL2968548 0.85 IGF1R (0.42) IGF1RNR4A2KMT2APOLBTHRB
SCHEMBL2960233 0.84 IGF1R (0.43) IGF1RNR4A2MEN1KMT2APOLB
SCHEMBL2968384 0.84 MRGPRX4 (0.49) IGF1RNR4A2POLBMAPK1L3MBTL1
SCHEMBL2968428 0.83 IGF1R (0.48) IGF1RNR4A2MEN1KMT2APOLB
SCHEMBL2957627 0.82 IGF1R (0.40) IGF1RNR4A2MEN1KMT2APOLB
SCHEMBL2955700 0.82 IGF1R (0.45) IGF1RNR4A2KMT2APOLBTHRB
SCHEMBL2970983 0.79 NR4A2 (0.42) IGF1RNR4A2KMT2APOLBTHRB
SCHEMBL2967444 0.79 IGF1R (0.41) IGF1RNR4A2POLBL3MBTL1
SCHEMBL2961143 0.78 IGF1R (0.40) IGF1RNR4A2KMT2APOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 IGF1R 4518/4885NR4A2 2293/4885MEN1 4571/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 IGF1R 4518/4885NR4A2 2293/4885MEN1 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.